These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 28178698

  • 21. Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study.
    Hong S, Han K, Park CY.
    Mayo Clin Proc; 2020 Jan; 95(1):101-112. PubMed ID: 31812252
    [Abstract] [Full Text] [Related]

  • 22. Dipeptidyl peptidase-4 inhibitor and insulin combination treatment in type 2 diabetes and chronic kidney disease: A meta-analysis.
    Zhou X, Shi H, Zhu S, Wang H, Sun S.
    J Diabetes Investig; 2022 Mar; 13(3):468-477. PubMed ID: 34551206
    [Abstract] [Full Text] [Related]

  • 23. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis.
    Tricco AC, Antony J, Khan PA, Ghassemi M, Hamid JS, Ashoor H, Blondal E, Soobiah C, Yu CH, Hutton B, Hemmelgarn BR, Moher D, Majumdar SR, Straus SE.
    BMJ Open; 2014 Dec 23; 4(12):e005752. PubMed ID: 25537781
    [Abstract] [Full Text] [Related]

  • 24. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
    Chen M, Liu Y, Jin J, He Q.
    Ren Fail; 2016 Dec 23; 38(4):581-7. PubMed ID: 26915531
    [Abstract] [Full Text] [Related]

  • 25. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
    Cooper ME, Perkovic V, McGill JB, Groop PH, Wanner C, Rosenstock J, Hehnke U, Woerle HJ, von Eynatten M.
    Am J Kidney Dis; 2015 Sep 23; 66(3):441-9. PubMed ID: 25960304
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis.
    Park H, Park C, Kim Y, Rascati KL.
    Ann Pharmacother; 2012 Nov 23; 46(11):1453-69. PubMed ID: 23136353
    [Abstract] [Full Text] [Related]

  • 27. Effect of dipeptidyl peptidase-4 inhibitors on tumor necrosis factor alpha levels in patients with type 2 diabetes mellitus.
    Zhao L, Meng J, Bai X, Zhang D, Yang X, Yang Y, Cai G, Liu X.
    Eur J Med Res; 2024 Jul 12; 29(1):363. PubMed ID: 38997754
    [Abstract] [Full Text] [Related]

  • 28. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I, Zhang R, Mamza JB, Ford M, Morris T, Banerjee A, Khunti K.
    Diabetes Obes Metab; 2022 Nov 12; 24(11):2138-2147. PubMed ID: 35676798
    [Abstract] [Full Text] [Related]

  • 29. A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials.
    Deacon CF.
    Diabetes Obes Metab; 2018 Feb 12; 20 Suppl 1():34-46. PubMed ID: 29364584
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R, Aguilar R, Hehnke U, Woerle HJ, von Eynatten M.
    Clin Ther; 2014 Nov 01; 36(11):1595-605. PubMed ID: 25236917
    [Abstract] [Full Text] [Related]

  • 31. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis.
    Wang B, Sun Y, Sang Y, Liu X, Liang J.
    Medicine (Baltimore); 2018 Nov 01; 97(46):e12633. PubMed ID: 30431561
    [Abstract] [Full Text] [Related]

  • 32. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I.
    Endocr Pract; 2017 Jul 01; 23(7):831-840. PubMed ID: 28332871
    [Abstract] [Full Text] [Related]

  • 33. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
    Chen JJ, Wu CY, Jenq CC, Lee TH, Tsai CY, Tu HT, Huang YT, Yen CL, Yen TH, Chen YC, Tian YC, Yang CW, Yang HY.
    JAMA Netw Open; 2022 Mar 01; 5(3):e221169. PubMed ID: 35254430
    [Abstract] [Full Text] [Related]

  • 34. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
    Scheen AJ.
    Diabetes Metab; 2020 Jun 01; 46(3):186-196. PubMed ID: 32007623
    [Abstract] [Full Text] [Related]

  • 35. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials.
    Esposito K, Chiodini P, Maiorino MI, Bellastella G, Capuano A, Giugliano D.
    BMJ Open; 2014 Jun 10; 4(6):e005442. PubMed ID: 24916090
    [Abstract] [Full Text] [Related]

  • 36. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G, Garofolo M, Del Prato S.
    Nutr Metab Cardiovasc Dis; 2016 May 10; 26(5):361-73. PubMed ID: 27105869
    [Abstract] [Full Text] [Related]

  • 37. Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Zhang F, Xu S, Tang L, Pan X, Tong N.
    Front Endocrinol (Lausanne); 2020 May 10; 11():288. PubMed ID: 32582019
    [Abstract] [Full Text] [Related]

  • 38. Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
    Richard KR, Shelburne JS, Kirk JK.
    Clin Ther; 2011 Nov 10; 33(11):1609-29. PubMed ID: 22071236
    [Abstract] [Full Text] [Related]

  • 39. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis.
    Liu D, Jin B, Chen W, Yun P.
    BMC Pharmacol Toxicol; 2019 Mar 04; 20(1):15. PubMed ID: 30832701
    [Abstract] [Full Text] [Related]

  • 40. A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis.
    Farah D, Leme GM, Eliaschewitz FG, Fonseca MCM.
    Diabetes Res Clin Pract; 2019 Mar 04; 149():47-63. PubMed ID: 30710655
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.